Recently, a real-world study showing association between incretin-based therapy and changes in taste perception with GLP-1 or dual GLP-1/GIP-RAs usage for around 40 weeks reported that independently to weight loss, there was an increase in sweet perception intensity up to 4.7 times and salt perception up to 3.2 times in around 20% of the participants, resulting as well in earlier satiety, and reduction of hunger and craving due to a major sensibilization to both flavors with any of these medication, although they did not mention further impact in weight loss or BMI change (170)
Or so its popularity suggests: The diabetes medication, which can lead to loss of up to 15% of body weight, is in such a demand-generated shortage that Novo Nordisk decided to pause Wegovy advertising.
Hey, endometriosis isn't just period pain, and I don't just want the birth control pill
Best day of the week for your GLP-1 shot For weekly formulations, the day you choose matters almost as much as the time
Novo Nordisk, the company responsible for Ozempic and Wegovy, clarified in a statement that women who were trying to conceive were excluded from early clinical trials of GLP-1 RAs like Ozempic